A Phase 3 Randomized, Double-Blind, Parallel-Group, Multi-Center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalisation.
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Apixaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms ADOPT
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2017 Results of pooled data from four randomized trials (EXCLAIM, ADOPT, MAGELLAN, and APEX trials) assessing qualitatively and quantitatively risk-benefit profile of extended-duration pharmacologic prophylaxis using the bivariate analysis, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
- 17 Nov 2011 Status changed from recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History